SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharmaceutical to acquire remaining stake in Taro Pharmaceutical Industries

18 Jan 2024 Evaluate

Sun Pharmaceutical Industries has entered into a definitive merger agreement with Taro Pharmaceutical Industries (Taro) to acquire all of the outstanding ordinary shares of Taro other than the shares already held by Sun Pharma. Sun Pharmaceutical will acquire 8,086,818 shares constituting 21.52% of the total outstanding shares of Taro for a cash consideration of $43 per share amounting to Rs 2,891.76 crore. 

Upon completion of the merger, currently expected to close in the first half of 2024, Taro will become a privately held company and its shares will no longer be listed on the NYSE.

Sun Pharmaceutical Industries is among the largest specialty generic pharmaceutical company and India's top pharmaceutical company.

Sun Pharma. Inds. Share Price

1862.15 -12.55 (-0.67%)
25-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1862.15
Dr. Reddys Labs. 1350.00
Cipla 1440.30
Zydus Lifesciences 1101.50
Lupin 2342.15
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: